A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies

Summary

This is a Phase 1, open label, non-randomised, dose-escalation single agent study with expansion cohorts for dose confirmation/safety and preliminary efficacy of QLS31901 in advanced or metastatic malignancies

Timeline

Start

2021-06-02

Primary completion

2022-12-30

Completion

2022-12-30

Drugs

Indications